Skip to Main Content

Paper Details

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.
Mol Ther
12
2022
Author NameAffiliation
Wanting HanCenter for Personalized Cancer Therapy, University of Massachusetts, University of Massachusetts Boston
Eva CoreyUniversity of Washington
Housheng Hansen HeUniversity of Toronto, Canada Princess Margaret Cancer Center, University Health Network
Shuai GaoCenter for Personalized Cancer Therapy, University of Massachusetts, University of Massachusetts Boston
Steven P BalkBeth Israel Deaconess Medical Center and Harvard Medical School
Changmeng CaiCenter for Personalized Cancer Therapy, University of Massachusetts, University of Massachusetts Boston
  • 1 - 6

Datasets